Provided By GlobeNewswire
Last update: Oct 3, 2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.
Details for the poster presentations are as follows:
NASDAQ:HOWL (11/7/2025, 12:41:53 PM)
1.095
-0.1 (-8.75%)
Find more stocks in the Stock Screener


